One year following the approval of the gemcitabine intravesical system, Joseph Jacob, MD, reflects on the expanding treatment landscape in BCG-unresponsive NMIBC.
|Articles|July 21, 2014
Urology Nevada survivor: ‘Why waste time on anger?’
Urologist Christine N. Lajeunesse, MD, who survived the shooting at Urology Nevada 7 months ago, tells a local TV station that her recovery is progressing and that she’s only angry she didn't get to tell the shooter “that he missed.”
Advertisement
Urologist Christine N. Lajeunesse, MD, who survived the shooting at Urology Nevada 7 months ago, tells a local TV station that her recovery is progressing and that she’s only angry she didn't get to tell the shooter “that he missed.”
To watch News4’s video report,
To get weekly news from the leading news source for urologists,
Advertisement
Related to this article
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
The PDUFA target action date is in the fourth quarter of 2026.
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Pearls & Perspectives: Expanding Sexual Health Conversations Through Digital Media, With Wendy Brant
Amy Pearlman, MD, and Wendy Brant discuss building a digital audience, navigating sexual health content online, and the role of communication in relationships.
Positive safety and efficacy data from 4 clinical studies supported the CE marking.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.
Advertisement
Advertisement
Trending on Urology Times
1
The Evolving Landscape of Minimally Invasive BPH Therapy
2
TURP, HoLEP, and the Future of Minimally Invasive BPH Therapy
3
FDA grants 510(k) clearance to SpaceOAR Flex Hydrogel for prostate radiotherapy
4
One year of Inlexzo: Evolving care in BCG-unresponsive NMIBC
5